ROSALIND

• Research type

  Research Study

• Full title

  Analysing and solving exceptional long-term survivors in solid tumors with poor prognosis

• IRAS ID

  340201

• Contact name

  Thankamma Ajithkumar

• Contact email

  thankamma.ajithkumar@nhs.net

• Sponsor organisation

  CURE51

• Duration of Study in the UK

  1 years, 9 months, 29 days

• Research summary

  We propose for the first time to build a large collection of samples from unexpected cancer survivors and controls patients (standard survival) to identify biomarkers of resistance and/or survival which would help developing new cancer therapeutics.
  This retrospective, exploratory, multicentre 3 cohorts case control (1/1) matched study will be conducted in patients with:
  - metastatic pancreatic ductal adenocarcinoma (PDAC),
  - extensive small cell lung cancer (SCLC) and
  - glioblastoma IDH wild type (GBM-IDH-wt).
  In the three disease cohorts, 170 patients/cases who had an exceptional long-term survival (case group) will be matched to a control case (standard survival group). Exceptional long-term survival will be defined as survival over 5 years for the cohorts of PDAC and SCLC and over 3 years for the cohort of GMB-IDHwt from the day of diagnosis. Biological samples and clinical records on a total of 1020 cases worldwide will be collected, centralized and analyzed.
  In addition to the clinical records describing the history of the patient (including multiscale imaging, pathology, biological sample analysis), we will collect every data possible with current biology sciences technologies (multi-omics) including genome, proteome, transcriptome, epigenomic, metabolome and microbiome. These data will be integrated and scrutinized to identify complementary effects and synergistic interactions between omic layers in the life course. Artificial intelligence (AI), specifically machine learning algorithms, will also help to understand these multi-omics data. After interpreting the comprehensive data set with our specialists in bioinformatic and European academic experts in PDAC, GBM and SCLC, we expect to find molecular signatures and consequently new therapeutic approaches to address patients and physicians unmet needs.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  24/EE/0190

• Date of REC Opinion

  17 Sep 2024

• REC opinion

  Further Information Favourable Opinion